rifampin and Central-Serous-Chorioretinopathy

To compare the efficacy of oral propranolol, oral rifampicin, and intravitreal anti-VEGF therapies on resolution-time and visual outcome in patients with central serous chorioretinopathy (CSCR).. A total of 30 patients with CSCR were randomized into three groups of 10 patients. Group A was given oral propranolol, Group B was given oral rifampicin 4 weeks each, and Group C was given 0.05 ml intravitreal injection of anti-VEGF. Comparisons of mean BCVA, contrast sensitivity, and central macular thickness (CMT) performed between baseline and follow-up at 4 weeks, 6 weeks, and 3 months.. Statistically significant improvement in BCVA and contrast sensitivity was noted among all three groups. Complete resolution of SRF as indicated by CMT was seen at the end of 4 weeks in Group C, whereas there was a steady decline in CMT until 3 months in Groups A and B.. Intravitreal anti-VEGF therapy shows a significantly faster SRF resolution. However, oral propranolol and oral rifampicin could prove as a useful, cost-effective treatment of CSCR.

Topics: Central Serous Chorioretinopathy; Humans; Intravitreal Injections; Propranolol; Rifampin; Tomography, Optical Coherence; Treatment Outcome

Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Choroid; Dose-Response Relationship, Drug; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Male; Nucleic Acid Synthesis Inhibitors; Retina; Rifampin; Tomography, Optical Coherence

To investigate the effect of oral Rifampin in patients with chronic central serous chorioretinoapthy (CSCR).. This was a prospective pilot study of patients with chronic CSCR with persistent subretinal fluid (SRF) for at least 3 months, who were treated with oral Rifampin 300 mg twice per day for 3 months and had 6 months of follow-up. All patients underwent a complete ocular examination and a spectral domain optical coherence tomography (SD-OCT) scan monthly from baseline until month 4, and then at month 6. Fluorescein angiography (FA) was performed at baseline and at the end of the study.. Fourteen eyes of 12 patients were included in the study, nine men and three women. Mean age was 58.5 years (range 32-80). Mean duration of SRF prior to study entry was 28.4 months. Forty-two percent of eyes were treated previously for CSR with thermal laser, PDT, or intravitreal bevacizumab. Mean best corrected visual acuity (BCVA) at presentation was 20/60 and improved to a mean of 20/50 at month 3 (P > 0.05). Retinal thickness was reduced by 25.3 %, 21.2 %, and 21 % on months 1, 2, 3, respectively (P < 0.05). Mean choroidal thickness at presentation was 476 μ (SD 188 μ) decreasing to 427 μ (SD 125 μ) after 3 months of treatment (P > 0.05). SRF was reduced in nine eyes (64 %) and completely resolved in six eyes (42.8 %) at month 3 following 3 months of treatment, and four out of these six eyes remained fluid free at month 6. Two patients stopped the treatment after 2 months due to adverse events.. Oral Rifampin may be a therapeutic option in patients with longstanding chronic CSCR.

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Central Serous Chorioretinopathy; Chronic Disease; Cytochrome P-450 CYP3A Inducers; Female; Fluorescein Angiography; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Retina; Rifampin; Subretinal Fluid; Tomography, Optical Coherence; Visual Acuity

The authors present three cases of chronic central serous retinopathy in which rifampin was used for the utility of its oral delivery in remote care and as an alternative to photodynamic therapy when intravenous access was not possible. In each of these cases, a reduction of subfoveal fluid and improvement of visual acuity were achieved.

Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Chronic Disease; Cytochrome P-450 CYP3A Inducers; Fluorescein Angiography; Humans; Male; Middle Aged; Rifampin; Subretinal Fluid; Tomography, Optical Coherence; Visual Acuity

The purpose of this report is to present a case of hepatotoxicity secondary to off-label rifampin therapy for the treatment of chronic central serous choroidopathy.. Case report.. A patient with chronic central serous chorioretinopathy was treated with oral rifampin. Three weeks after the initiation of therapy, fatigue, nausea, and malaise associated with elevated liver enzyme elevations were noted. Symptoms resolved and liver enzymes normalized after discontinuing rifampin.. Rifampin-induced hepatic injury can occur during therapy for chronic central serous chorioretinopathy. Potential hepatotoxicity must be considered and followed closely during off-label rifampin treatment.

Topics: Aged; Central Serous Chorioretinopathy; Chemical and Drug Induced Liver Injury; Chronic Disease; Humans; Male; Nucleic Acid Synthesis Inhibitors; Rifampin

Chronic central serous retinopathy (CSR) is characterised by frequent exacerbations and a poor visual prognosis. Very few therapies exist for chronic CSR, and the existing therapies are often ineffective. Thus, novel therapies to combat this frustrating disorder are needed. Presented here is a case detailing a patient with chronic CSR with persistent subfoveal fluid of 2 years' duration that completely resolved with 1 month of oral rifampin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favourably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSR manifestations.

Topics: Administration, Oral; Aged; Cataract Extraction; Central Serous Chorioretinopathy; Chronic Disease; Cytochrome P-450 CYP3A; Humans; Male; Nucleic Acid Synthesis Inhibitors; Postoperative Complications; Remission Induction; Rifampin